NEW YORK (
CHANGE IN RATINGS
Bank of Hawaii
downgraded at Credit Suisse to Neutral from Outperform on relative valuation. Price target trimmed by a dollar to $60. Estimates cut through 2012.
downgraded at KBW from Outperform to Market Perform. Valuation call, based on a $39 price target.
rated new Hold at Jefferies. $38 price target. Valuation call, though the company has attractive growth potential.
downgraded at Citigroup from Buy to Hold. Valuation call, based on a $110 price target.
downgraded at Merriman from Buy to Neutral. Valuation call, though the shift toward streaming movies should boost margins.
rated new Positive at Susquehanna. Coverage of NTAP was started with a Positive rating. $41 price target. Company could return to high-teens sales growth.
upgraded at Oppenheimer from Underperform to Perform. $7 price target. Industry is a late-cycle retail play.
upgraded at Barclays to Equal Weight from Underweight as the company should benefit from improved hospital capital spending trends. Price target jumped to $62 from $56.
rated new Market Perform at Wells Fargo. Investors have high expectations for the company's hepatitis drug, telaprevir.
The Street Ratings
STOCK COMMENTS / EPS CHANGES
estimates, target cut at UBS. Shares of AEO now seen reaching $17. Estimates also reduced, as inventory is high, which could lead to higher markdown activity. Neutral rating.
target cut at Goldman. APC target was lowered to $83. Company could be hurt even further by the oil spill. Neutral rating.
numbers raised at FBR. Shares of GIL now seen reaching $31. Estimates also increased, as the company is gaining market share and raising prices. Market Perform rating.
estimates reduced at Goldman through 2012. Company is facing higher compensation costs. Neutral rating and $49 price target.
estimates, target raised at Goldman. Shares of LM now seen reaching $34. Estimates also increased, given better investment performance. Neutral rating.
estimates, target lowered at Morgan Stanley. MON estimates were reduced through 2012. Expect further disappointments from Roundup. Overweight rating and new $70 price target.
estimates increased at FBR through 2012. Company is seeing better results, aided by lower interest expenses.
target upped at Morgan Stanley to $49. Product pricing appears firm so far this quarter. Overweight rating.
This article was written by a staff member of TheStreet.com.